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It has been proposed that hyaluronan-binding
proteoglycans play an important role as guiding cues
during neural crest (NC) cell migration, but their precise
function has not been elucidated. In this study, we
examine the distribution, structure and putative role of
the two major hyaluronan-binding proteoglycans, PG-
M/versicans and aggrecan, during the course of avian NC
development. PG-M/versicans V0 and V1 are shown to be
the prevalent isoforms at initial and advanced phases of
NC cell movement, whereas the V2 and V3 transcripts are
first detected following gangliogenesis. During NC cell
dispersion, mRNAs for PG-M/versicans V0/V1 are
transcribed by tissues lining the NC migratory pathways,
as well as by tissues delimiting nonpermissive areas.
Immunohistochemistry confirm the deposition of the
macromolecules in these regions and highlight regional
differences in the density of these proteoglycans. PG-
M/versicans assembled within the sclerotome rearrange
from an initially uniform distribution to a preferentially
caudal localization, both at the mRNA and protein level.
This reorganization is a direct consequence of the
metameric NC cell migration through the rostral portion
of the somites. As suggested by previous in situ
hybridizations, aggrecan shows a virtually opposite
distribution to PG-M/versicans being confined to the
perinotochordal ECM and extending dorsolaterally in a
segmentally organized manner eventually to the entire
spinal cord at axial levels interspacing the ganglia. PG-
M/versicans purified from the NC migratory routes are
highly polydispersed, have an apparent Mr of 1,200-2,000
kDa, are primarily substituted with chondroitin-6-
sulfates and, upon chondroitinase ABC digestion, are
found to be composed of core proteins with apparent Mr
of 360-530,000. TEM/rotary shadowing analysis of the
isolated PG-M/versicans confirmed that they exhibit the
characteristic bi-globular shape, have core proteins with
sizes predicted for the V0/V1 isoforms and carry
relatively few extended glycosaminoglycan chains.
Orthotopical implantation of PG-M/versicans
immobilized onto transplantable micromembranes tend
to ‘attract’ moving cells toward them, whereas similar
implantations of a notochordal type-aggrecan retain both
single and cohorts of moving NC cells in close proximity
of the implant and thereby perturb their spatiotemporal
migratory pattern. NC cells fail to migrate through three-
dimensional collagen type I-aggrecan substrata in vitro,
but locomote in a haptotactic manner through collagen
type I-PG-M/versican V0 substrata via engagement of
HNK-1 antigen-bearing cell surface components. The
present data suggest that PG-M/versicans and
notochordal aggrecan exert divergent guiding functions
during NC cell dispersion, which are mediated by both
their core proteins and glycosaminoglycan side chains
and may involve ‘haptotactic-like’ motility phenomena.
Whereas aggrecan defines strictly impenetrable
embryonic areas, PG-M/versicans are central
components of the NC migratory pathways favoring the
directed movement of the cells.
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INTRODUCTION
It has been proposed that hyaluronan-binding (hyalectans)
proteoglycans of large Mr indiscriminately exert a negative
influence during neural crest (NC) cell migration by
functioning as spatially restricting molecules for the dispersing
NC cells (Erickson and Perris, 1993; Henderson and Copp,
1997; Perris, 1997). In fact, xenographic transplantations of
notochordal tissue in the vicinity of the neural tube inhibit cell
movement locally and in a developmentally dependent fashion
(Pettway et al., 1990, 1996), whereas ablation of the
endogenous notochord causes abnormal ganglion formation
(Teillet and Le Douarin, 1983; Tosney and Oakley, 1990; Stern
et al., 1991). The observed effects seem to be imputable to its
primary ECM proteoglycan, aggrecan, as shown by antibody
blockade experiments and chondroitinase ABC digestions of
the notochordal tissue implants (Pettway et al., 1990, 1996).
These findings are also supported by the pronounced inhibitory
effects of aggrecan on avian and amphibian NC cell motility
in vitro (Perris and Johansson, 1987, 1989; Perris et al., 1991a,
1996; Kerr and Newgreen, 1997), and are further supported by
the failure of ectopically introduced avian aggrecan to rescue
migration of pigment cell precursors in the proteoglycan-
deficient white mutant embryo of the Mexican axolotl (Olsson
et al., 1996).
Whereas these previous studies emphasize a negative
influence of aggrecan on NC cell movement, the putative role
of hyaluronan-binding PG-M/versicans remains ambiguous.
Their patterned distribution within the somites (Tan et al.,
1987; Landolt et al., 1995; Henderson et al., 1997) and the
triggering of a precocious dorsolateral NC cell migration
following surgical ablation of the dermomyotome (which is
accompanied by an apparent reduction in chondroitin sulfate-
bearing proteoglycans deposited into the subectodermal space;
Oakley et al., 1994), suggest that these proteoglycans could
similarly function as potential ‘barriers’ for NC cell movement.
However, it is unclear whether this patterned distribution is a
cause, or a consequence, of the metameric NC cell migration
within the sclerotome and it is not possible to preclude that the
alteration in migratory behaviour of NC cells could be due to
other morphogenetic anomalies caused by ablation of the
dermomyotome tissue.
Two observations provide further contrasting data regarding
the possible role of PG-M/versicans during NC development.
First, the deficient expression of PG-M/versicans in the
subectodermal region of the white mutant Mexican axolotl
embryo is intimately associated with the failure of NC cells to
migrate dorsolaterally (Perris et al., 1990; Stigson and Kjellen,
1991; Stigson et al., 1997a,b). Secondly, in the splotch (Sp2H)
mouse mutant carrying abnormalities in the Pax3 gene
(speculated to be a potential upstream regulator of the PG-
M/versican gene), aberrant expression of PG-M/versicans
correlates with disturbed NC cell migration (Henderson et al.,
1997). It should also be noted that deletion of the murine PG-
M/versican gene by insertional mutagenesis causes embryonic
death due to abnormal heart chamber formation (Mjaavedt et
al., 1998); this process is known to require the contribution of
NC derivatives and substantial PG-M/versican deposition
(Henderson and Copp, 1998).
PG-M/versicans, which are central ECM constituents in a
number embryonic and adult tissues, have been characterized
structurally and biochemically in several species (Kimata et al.,
1986; Habuchi et al., 1986; Mörgelin et al., 1989; Morita et al.,
1990; Perides et al., 1992; Yamagata et al., 1986, 1993;
Shinomura et al., 1993; Carrino et al., 1994; Dours-
Zimmermann and Zimmermann, 1994; Yao et al., 1996;
Stigson and Kjellen, 1991; Stigson et al., 1997a; Schmalfeldt
et al., 1998). Studies in avians, mice and man have established
that at least four different isoforms can be generated by exon
skipping from a larger transcript denoted V0 (Shinomura et al.,
1993, 1995; Dours-Zimmermann and Zimmermann, 1994; Ito
et al., 1995; Zako et al., 1995). Since these isoforms vary in
the relative content of one or both of the two chondroitin
sulfate-attachment domains, CSa and CSb , proteoglycans with
entirely divergent functions could be expressed in different
tissues and at different phases of development. Furthermore,
the identification of an additional avian-specific spliced exon,
analogous to that encoding the keratan sulfate-attachment
domain of aggrecan (Zako et al., 1997), widens the repertoire
of potential PG-M/versican isoforms and suggests that, in some
tissues, these proteoglycans may carry keratan sulfate moieties.
In the present study, we have mapped the expression pattern
of PG-M/versican isoforms and determined the in situ
distribution of both PG-M/versicans and aggrecan during the
course of NC cell development in the chick embryo. PG-
M/versicans synthesized during the course of trunk NC cell
movement were isolated, analyzed ultrastructurally and
partially characterized immunochemically/biochemically. The
potential function of PG-M/versicans and aggrecans in vivo
and in vitro was then comparatively examined by implanting
the purified molecules heteropically into the migratory
pathways of the NC, via prior immobilization onto
micromembranes and determining the capacity of cultured NC
cells to migrate through three-dimensional collagen type I-
proteoglycan substrata. The results are consistent with a
predominant expression of the PG-M/versican V0 and V1
isoforms during early phases of avian embryonic development
and point to diverse roles for PG-M/versicans and aggrecan
during NC cell migration.
MATERIALS AND METHODS
Purified mammalian and avian proteoglycans
Hyaluronan-aggrecan complexes stabilized by link protein were
purified from bovine nasal cartilage and cultured chondrosarcoma
cells as described in Mörgelin et al., (1992). The chick cartilage
aggrecan and the avian PG-M/versican V0 isoform were obtained
from sternal cartilage from 12-days old chick embryos and cultured
chick tendon fibroblasts, respectively, as previously described
(Shinomura et al., 1983; Yamagata et al., 1986). Since according to
our characterization (Perris et al., 1991a, 1996; data not shown) this
aggrecan is structurally and immunologically identical to that
expressed by the developing notochord (Domowicz et al., 1995), we
refer to it as ‘notochordal-like’ aggrecan throughout the study. The
bovine aorta PG-M/versicans V1/V2 were provided by Dick
Heinegård (Department for Cell and Molecular Biology, University of
Lund, Sweden) and purified in this study according to a novel
purification scheme (M. Schiappacassi, D. P., S. Cattaruzza, P.
Spessotto, A. C. and R. P., unpublished data). Previously published
data (Kimata et al., 1986; Yamagata et al., 1986), and our recent
ultrastructural and compositional analysis of the PG-M/versicans V0
isoform from cultured chick fibroblasts and V1/V2 isoforms from
bovine aorta (Mörgelin et al., 1989; Perris et al., 1996; M.
D. Perissinotto and others
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Schiappacassi, D. P., S. Cattaruzza, P. Spessotto, A. C. and R. P.,
unpublished data), indicate substantial differences in the
glycosaminoglycan chain composition of these proteoglycans: the
former contains numerous, longer chains primarily composed of
unusually oversulfated chondroitin-6-sulfate and some minor amounts
of unsulfated and 4-sulfated chondroitin, whereas the latter have
fewer, shorter chains mainly composed of chondroitin-4-sulfate and
dermatan sulfate and no detectable amounts of unsulfated chondroitin
and chondroitin-6-sulfate.
Source and specificity of anti-proteoglycan antibodies
The characteristics of the antibodies against proteoglycans used in
this study are summarized in Table 1. The previously indicated
specificities of some of these antibodies were further ascertained
here by ELISA, dot-blotting and western blotting utilizing a number
of purified proteoglycans and recombinant fragments. mAb 5D5
(kindly provided by Firoz Rahemtulla, University of Alabama,
Birmingham, AL) recognizes a highly conserved epitope shared by
its immunogen, human (Perides et al., 1992), bovine (M.
Schiappacassi, D. P., S. Cattaruzza, P. Spessotto, A. C. and R. P.,
unpublished data), avian (this study) and axolotl (not shown) PG-
M/versicans, but fails to react with aggrecan. The use of CNBr-
derived fragments of the fibroblast PG-M/versican V0 has
previously shown that the epitope of mAb MY174 against avian PG-
M/versicans resides within chondroitin sulfate-free fragments
ranging from 45-100 kDa (Yamagata et al., 1993). Our present data
indicate that it recognizes a partially masked epitope on isoforms
V0/V1 isoforms and/or PG-M/versicans with specific glycosylation
traits. Specificity of the anti-avian PG-M/versican antiserum have
been described elsewhere (Shinomura et al., 1993). The antiserum
A1 (kindly provided by Maurizio Pacifici, Dental School, University
Pennsylvania, Philadelphia, PA) reacts with early and late expressed
chick notochordal aggrecan (Oettinger et al., 1985) and does not
react with PG-M/versicans. mAbs 5C12, 4G2, 4C5 and 2E12 were
generated by immunization of mice with the bovine aorta PG-
M/versicans V1/V2 according to standard protocols. mAbs 5C12
and 2C12 react with N-linked oligosaccharides carrying terminal
fucose residues that are present on PG-M/versicans of various
species and are susceptible to chondroitinase ABC digestion,
whereas mAb 4C5 reacts with native chondroitin-4-sulfate. Further
details about the production and specificity of these mAbs are
reported elsewhere (M. Schiappacassi, D. P., S. Cattaruzza, P.
Spessotto, A. C. and R. P., unpublished data). mAb CS56 against
chondroitin sulfates was purchased from Sigma.
RT-PCR and RNase protection assays (RPA)
Since the precise location of the splice sites for V2 and V3 mRNAs
are described for the mouse and human, but not for the chick PG-
M/versican gene, we aligned the mouse and chick nucleotide
sequences and derived the corresponding avian splicing sites. The
oligonucleotides synthesized for RT-PCR were: 
AAG TTA ACC ACC CTT TTA CCT (PGM-A, sense), nucleotides
1432-1452; 
TCA ACT GCT ACT GCA GTT G CAC (PGM-B, sense),
nucleotides 4225-4246; 
CAC TTG TTG CTT TCC ATT GAT G (PGM-C, antisense),
nucleotides 4617-4638; 
and T GAG GCC ATC TAT ACA TGT GGC (PGM-D, antisense),
nucleotides 10057-10078. 
Exanucleotides were used to synthesize cDNA from total RNAs
from midtrunk segments of stage 15-25 chick embryos using AMV
Reverse Transcriptase (Promega). For the precise assessment of the
developmentally related RNA expression levels of the V0-V3
transcripts by RPA, amplified and cloned riboprobes were linearized
with the appropriate enzymes for the recombinant vectors and 32P-
labelled antisense RNA riboprobes were synthesized from SP6 or T7
promoters with 20 units each of SP6 and T7 RNA polymerase
(Promega), respectively, and annealed with 10-20 m g of total RNA.
RPA was carried using the RPA II kit (Ambion) according to the
instructions provided by the supplier. Briefly, RNA was digested with
200 m l of a RNase A/RNase T1 mixture (solution R) diluted 1:100 in
RNase digestion buffer (solution Bx) at 37°C for 30 minutes. The
undigested fragments were precipitated by treatment with 300 m l of
Dx solution and cooling to - 20°C for 15 minutes. The fragments
obtained were run on 5% polyacrylamide gel in the presence of 6 M
urea and visualized by autoradiography on Hyperfilm MP
(Amersham). Calibration of the amount RNA loaded onto each lane
was accomplished by independent agarose gel runs, using a chick b -
actin probe as reference. Autoradiograms were produced at different
exposure times; those in which the signal for the protected transcripts
had reached saturation were photographed. Assessment of the relative
levels of expression of the protected transcripts was accomplished by
analyzing autoradiograms in the linear exposure range by computer-
assisted densitometry using a Philips CCD video camera and the
GelScan software. Densities of the autoradiographic bands obtained
for each individual isoform were plotted accounting for the specific
intensities in 32P-activity of the differently sized fragments. Direct
comparisons of the relative levels of expression of the individual
isoforms at the given developmental stages are reported in per cent,
Table 1. Characteristics of anti-proteoglycan antibodies
Antibody Immunogen (species) Reactivity Epitope location
MY174 PG-M/versican V0 (avian) PG-M/versicans SPLICE domain1
5D5 PG-L2 (avian) PG-L/PG-M/versicans V0-V2 CS b domain3
2C12 PG-M/versican V1/V2 (bovine) PG-M/versicans V0-V2 N-oligoS-Fuc4
4G2 PG-M/versican V1/V2 (bovine) PG-M/versicans V0-V2 ?
4C5 PG-M/versican V1/V2 (bovine) PG-M/versicans V0-V2 Chondroitin-4-sulfate
5C12 PG-M/versican V1/V2 (bovine) PG-M/versicans V0-V2 N-oligoS-Fuc
anti-PG-M (antiserum) PG-M/versican V0 (avian) PG-M/versicans (whole molecule)
A1 (antiserum) cartilage aggrecan (avian) Aggrecan5 (whole molecule)
CS56 fibroblast ECM (avian) chondroitin sulfates domain 26
1According to the domain assignment of Shinomura et al. (1993)
2Refers to the high Mr chondroitin/dermatan sulfate proteoglycan isolated from bovine sclera
3Reactivity and epitope locations were determined by biochemical and immunochemical means in conjunction with TEM/rotary shadowing using purified
proteoglycans and recombinant proteins. These data are described in detail elsewhere (M. Schiappacassi, D. P., S. Cattaruzza, P. Spessotto, A. C. and R. P.,
unpublished data)
4The epitope resides in N-linked oligosaccharides containing fucose residues at the non-reducing end. In chick embryonic PG-M/versicans these
oligosaccharide moieties are susceptible to chondroitinase ABC digestion, whereas they are largely enzyme resistant in PG-M/versicans from bovine aorta (M.
Schiappacassi, D. P., S. Cattaruzza, P. Spessotto, A. C. and R. P., unpublished data)
5Recognizes both the early notochordal and mature cartilage aggrecan
6According to the domain assignment of Sorrell et al. (1993)
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adopting the signal obtained for the most abundantly expressed
isoform as 100%. The nature of the splicing sites permitted the direct
comparison of the V0-V2 mRNA signals on the same autoradiogram,
whereas the protected signal obtained for the V3 isoform was
normalized to the one obtained in the same autoradiogram for the
cumulative expression of V0-V2 mRNAs.
In situ hybridization
For radioactive and digoxigenin-based in situ hybridizations on whole
embryos and tissue sections from embryos at developmental stages
15-23, a set of four cDNAs was employed. Since the largest V0
transcript encompasses all alternatively spliced exons, all cDNAs used
in this study hybridize by default to this transcript, and hence, there
is technically no possibility of discriminating between V0 and V1
when both transcripts are coexpressed. Riboprobe specificity was as
follows.
Riboprobe Isoform specificity Corresponding nucleotides
M2a V0, V2 2623-3810
M4a V0, V1 7410-8406
M6a V0, V1, V2, V3 9909-10827
M7a V0, V1, V2, V3 10827-11649
cDNA probes were labelled with digoxigenin using the Boehringer
Mannheim’s DIG DNA labelling and detection kit according to the
procedure indicated by the manufacturer. Whole-mount in situ
hybridization was performed according to the protocol of Wilkinson
(1992). For in situ hybridization on tissue sections, embryos were
fixed in phosphate-buffered 4% PFA for 4 hours to overnight at 4°C,
rinsed in PBS and incubated in 5% sucrose for 1 hour at 4°C, followed
by incubation overnight in 15% sucrose. Embryos were then
embedded in OCT compound, cryosectioned and the sections were
mounted on Super Frost slides, followed by air-drying, fixation in
place with 4% PFA for 20 minutes at room temperature, dehydration
through a graded series of ethanol and further air-drying. The
prehybridization procedure involved a rehydration of the sections and
treatment with 3 m g/ml proteinase K in 10 mM Tris-HCl, pH 8.0, with
2 mM EDTA, for 15 minutes at 37°C. Sections were then washed in
PBS, fixed in 4% PFA for 20 minutes at room temperature, rewashed
and incubated for 10 minutes in 0.1 M triethanolamine, pH 8.0,
followed by acetylation with 0.25% acetic anhydride for 15 minutes
at room temperature. Sections were then washed in PBS and
prehybridized in 300 m l of 1 ml hybridization solution composed of
100 m M Tris-HCl, pH 7.5, with 0.15 M NaCl, 500 m l formamide, 200
m l of 20· SSC, 20 m l of 50· Denhardt’s solutions, 50 m l of heat-
denatured herring sperm DNA (10 mg/ml), 25 m l of yeast tRNA (10
mg/ml) and 200 m l 50% dextran sulfate solution for 3-5 hours at room
temperature in a humidified chamber. For hybridization, DIG-labelled
or [35S]UTP-labelled, heat-denatured riboprobes were dissolved at 0.2
m g/ml in hybridization solution and applied to the sections for 18-20
hours at 55°C. Thereafter, sections were sequentially incubated in 5 ·
SSC for 30 minutes at 55-60°C; 2· SSC containing 50% formamide
for 20 minutes at 50-55°C, 4 · SSC for 10 minutes at 37°C; 4 · SSC
containing 20 m g/ml RNase A for 30 minutes at 37°C; 4 · SSC for 10
minutes at 37°C; 2· SSC/50% formamide for 20 minutes at 55°C; 2 ·
SSC for 15 minutes at 37°C; and finally 0.1· SSC for 15 minutes at
37°C. Hybridized DIG-labelled probes were visualized using the DIG
detection kit, whereas sections hybridized with radioactive probes
were rinsed for 2 hours at 50°C in hybridization buffer, digested with
RNase A for 30 minutes at 37°C, washed, air-dried and dipped in
NTB-2 emulsion (Kodak; diluted 1:1 in H2O). Sections were then
exposed for different time periods at 4°C, developed, fixed and
mounted in DPX mounting medium.
Purification of PG-M/versicans from NC migratory
pathways
Embryos at stages 15-23 were explanted into Pannett-Compton
solution and 8- to 10-somite-long segments from the trunk region
extending from the wing bud to the hindlimb were excised, further
trimmed to remove the developing gut and pronephric ducts, and
immediately frozen in liquid N2. Explanted tissues were gently
homogenized on ice and extracted for 20-24 hours at 4°C with 4 M
GuHCl, 50 mM acetate buffer, pH 5.8, containing 1 mM PMSF, 10
mM NEM, 10 mM caproic acid, 10 mM benzamidine, 10 mM EDTA
and 0.2% Triton X-100. The extract was centrifuged at 14,000 g for
40 minutes and the supernatant was collected, dialyzed against 50 mM
Tris-HCl, pH 8.0, containing 7 M urea, 2 mM MgCl2, 0.2% Triton X-
100 and the same protease inhibitors, and digested with 50 m l
benzoase (Boehringer Mannheim) for 1 hour at 37°C. The digest was
then redialyzed and loaded onto a Sephadex G-50 column, which was
directly connected to DEAE-Sepharose Fast Flow column
(Amersham-Pharmacia). After loading of the sample, the two columns
were disconnected and the DEAE-Sepharose column was washed
with 5 volumes of washing buffer composed of 50 mM Tris-HCl, pH
8.0, 7 M urea, 0.4 M NaCl, 5 mM EDTA, 10 mM aminocaproic acid
and 10 mM benzamidine. The column was then eluted with 6 M
GuHCl in 50 mM acetate buffer, pH 5.8, 50 mM EDTA, 0.1% Triton
X-100 and the cocktail of protease inhibitors. Fractions containing the
proteoglycans of interest were selected by ELISA, or filtration dot-
blot assays in the Easy-Titer ELIFA device (Pierce), according to the
protocols indicated by the manufacturer and using mAbs 5D5, MY174
and CS56. The immunoreactive fractions were pooled and loaded onto
CL-2B Sepharose columns equilibrated with Tris-urea washing buffer
and eluted with the same buffer. In a separate set of experiments,
analytical CL-2B Sepharose gel permeation chromatograms were run
on extracts derived from ~ 100 embryo explants for each of the
developmental stages 15, 17 and 23. Eluted fractions were analyzed
by ELISA, dot-blot, SDS-agarose gel electrophoresis, involving
Alcian blue-silver staining (see below) and western blotting with the
above indicated mAbs. In these latter two cases, single fractions, or
pools of PG-M/versican-containing fractions identified by
ELISA/dot-blot, were precipitated with ethanol (1:9 v/v) in the cold
and resuspended in sample buffer for electrophoretic separation.
Preparative purifications of PG-M/versicans were carried out on
extracts of trunk segments from 150-300 embryos at stages 17-18 by
collecting the 5D5-positive proteoglycan pool obtained by gel
permeation chromatography on CL-2B Sepharose and by loading the
eluate onto DEAE-Sepharose columns (20 ml). These were then
eluted with a linear 0.3-2.0 M NaCl gradient in 20 mM Tris-HCl, pH
8.0, 7 M urea. Proteoglycans separated by the NaCl gradient were
examined by ELISA/dot-blot, SDS-PAGE, SDS-agarose gel
electrophoresis and western blotting using the anti-PG-M antiserum,
and mAbs 5D5, MY174, 2C12 and 5C12. These PG-M/versican
preparations were also used for coating of micromembranes to be
implanted into embryos (see below). Fractions containing PG-
M/versicans recognized by mAb 5D5 and the anti-PG-M/versican
antiserum were also pooled, dialyzed against 10 mM
piperazine/perchlorate buffer, pH 5.0, containing 6 M urea and 0.1%
CHAPS and further by chromatographed on a Mono-Q column eluted
with a linear 0-0.5 M gradient of LiClO4 in the same buffer. Eluted
fractions were analyzed as indicated above.
SDS-PAGE, SDS-agarose gel electrophoresis and western
blotting
Purified embryonic PG-M/versicans were analyzed in their intact form
by agarose gel electrophoresis, in the presence of SDS according to a
previously described procedure (Perris et al., 1996). Resolved
proteoglycans were visualized by combined silver and Alcian blue
staining according to the procedure of Min and Cowman (1985), and
further examined by western blotting using the panel of anti-
proteoglycan antibodies (Table 1). PG-M/versicans were also resolved
either intact, or after single and combined enzymatic digestions by
SDS-PAGE on gradient 3-8% gels, under reducing and non-reducing
conditions, and similarly analyzed by western blotting. For enzymatic
D. Perissinotto and others
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predigestions, proteoglycan-containing fractions were dialyzed
against 50 mM Tris-HCl, pH 7.6 (chondroitinase ABC, ACII and
heparitinase), or 50 mM sodium acetate buffer, pH 5.8 (keratanase I
and endo- b -galactosidase), and alternatively digested for 1 hour at
37°C with 0.3 U/ml of chondroitinase ABC, 0.3 U/ml of
chondroitinase ACII, 0.01 U/ml of keratanase I, 0.01U/ml of endo- b -
galactosidase and 0.02 U/ml of heparitinase III (Sigma). For western
blotting, PG-M/versicans resolved by SDS-PAGE, or SDS-agarose
electrophoresis, were electrolytically transferred onto nylon (Zeta
Probe, Bio-Rad), PVDF (Millipore) or nitrocellulose (Schleicher &
Schuell) membranes in standard transfer buffer at pH 6.5 for agarose
gels and pH 9.0 for polyacrylamide gels. Membranes were saturated
with 4% a -casein in 0.1 M bicarbonate buffer, pH 8.8, containing 1%
PVP 40,000 (Sigma) and 10 mM EDTA for 2-12 hours at room
temperature, and incubated with primary antibodies diluted in the
same solution as above, but with 1% a -casein and 0.15 M NaCl, to
1:1 (for supernatants) or 1:1,000 for ascites fluids and purified IgGs.
After extensive washings with the antibody-incubation buffer
supplemented with 0.3% Tween-20, membranes were further
incubated with secondary antibodies at 1:1,000 for 1 hour at room
temperature, washed and processed for chemiluminescence using the
ECL-Plus chemiluminescence kit (Amersham-Pharmacia). Apparent
Mrs above the 205,000 band of myosin II were determined in parallel
run Coomassie-blue-stained gels containing reduced and nonreduced
EHS laminin-1 ( ~ 400 kDa for the a 1 chain reduced; ~ 1,000 kDa for
the nonreduced heterotrimer), intact collagen type VI tetramers
( ~ 2,400 kDa), a purified IgM-class mouse immunoglobulin (950
kDa), and gel electrophoresis/gel filtration standards (Sigma),
comprising thyroglobulin (669 kDa), ferritin (440 kDa), b -catalase
(232 kDa), lactate dehydrogenase (140 kDa), b -galactosidase (106
kDa), phosphorylase (97 kDa) and BSA (67 kDa).
TEM and rotary shadowing
For TEM involving rotary shadowing, proteoglycan samples (final
concentration of 10 m g/ml) were dialyzed overnight against 0.2 M
ammonium hydrogen carbonate, pH 7.9, in a microdialysis apparatus
(5-50 m l, Biowerk), mixed with an equal volume of 80% glycerol and
prepared for ultrastructural analysis as previously described
(Mörgelin et al., 1989, 1992). Specimens were dried at high vacuum
for 1-2 hours and rotary shadowed at a 9° angle with
platinum/carbon, followed by coating with carbon at a 90° angle.
Replicas were floated onto distilled water and picked up on 400-mesh
copper grids. Electron micrographs were taken on a Zeiss 10
transmission electron microscope operated at 80 kV accelerating
voltage. Magnifications ( · 25,000) were calibrated by photography of
a calibration grid (Balzers) under the same electron optical
conditions. Measurements were performed on a screen after · 10
enlargement of the negatives. For ultrastructural analysis of the NC
cell-proteoglycan interaction in vivo, embryos that had received
proteoglycan-coated micromembranes were processed for TEM as
previously described (Perris et al., 1990).
Immunohistochemistry
Since optimal staining with the various anti-proteoglycan antibodies
required different fixation and embedding procedures, embryos at
developmental stages 15-24 were processed according to the
requirement of each antibody to be used. Thus, sections were prepared
from freeze-substituted and paraffin-embedded embryos as previously
described (Perris et al., 1991a), or from embryos fixed with 4%
paraformaldehyde for 1 hour at room temperature followed by quick
freezing in liquid N2 and embedding in OCT compound. Enzymatic
pretreatments with either testicular hyaluronidase and/or collagenases
did not alter the immunoreactive pattern observed (not shown).
Double immunolabellings with the antiserum A1 and antibody HNK-
1, or mAb CS56 and the biotinylated HNK-1 antibody, were carried
out using appropriate affinity-purified secondary antibodies and
FITC-, BODIPY- or Texas Red-conjugated streptavidin (Amersham-
Pharmacia). Another series of double-labellings were performed with
the anti-PG-M/versican antiserum and the HNK-1 antibody on
sections from embryos in which the NC had been locally ablated by
surgical removal of the neural folds (Perris et al., 1991b).
Implantation of purified proteoglycans bound to
micromembranes
Nucleopore polycarbonate circular sheets (13 mm in diameter; Costar)
with a pore size of 1-3 m m, which is by far larger than that allowing
free passage of migrating NC cells (Newgreen, 1989), were incubated
overnight at 4°C, or for 4 hours at 37°C, with human plasma
fibronectin (Collaborative Biochemical Products), the chick
notochordal-like aggrecan, multimeric hyaluronan-aggrecan
complexes from bovine nasal cartilage, the avian PG-M/versican V0,
the bovine aorta PG-M/versicans V1/V2, or PG-M/versicans V0/V1
purified from stage 22 chick embryonic trunks. In some cases, the
chick aggrecan was digested with chondroitinase ABC (Sigma) alone,
or with both chondroitinase ABC and endo-b -galactosidase (Sigma),
as previously described (Perris et al., 1996), and subsequently coated
onto the micromembranes. Since these are porous and they were
entirely immersed into the protein solution during coating, the
molecules were unavoidably adsorbed onto both sides of the
membranes. Relative coating efficiency was ascertained qualitatively
by indirect immunohistochemistry on micromembranes in vitro, or on
tissue sections derived from embryos that had received
micromembrane implants (not shown), and quantitatively by using
3H-labelled fibronectin, the notochordal-like aggrecan and a bovine
nasal cartilage aggrecan. In this latter case, the amount of protein
bound to the micromembranes was estimated to be 0.2-0.4 pmol/cm2,
at a coating concentration of 1,000 m g/ml and assuming the Mr of
440,000 and 240,000, respectively, for fibronectin and the
proteoglycans’ core proteins. Comparable coating efficiencies were
also detected for aggrecans, avian PG-M/versican V0 and bovine PG-
M/versican V1/V2 by solid-phase binding assays using biotinylated
molecules (data not shown). Micromembranes measuring
approximately 300· <100 m m prepared from coated and uncoated
membranes were extensively rinsed in Howard’s Ringer solution and
surgically implanted into various regions of the trunk at the level of
the last 4-6 somites formed. Embryos were excised from the egg,
rinsed in Pannett-Compton solution, fixed in Zenker’s fixative,
paraffin embedded and serially sectioned as previously described
(Pettway et al., 1990). Sections were processed for indirect
immunofluorescence using the HNK-1 antibody and analyzed in
either a Leitz Axiovert microscope or a computer-interfaced Bio-Rad
MCR 1024/Nikon Diaphot confocal laser microscope equipped with
the apposite image acquisition and analysis softwares.
Migration assay in vitro
NC cultures and preparation of fibronectin- and proteoglycan-
containing polymeric collagen type I (Col I) substrata in a delimited
area ( ~ 1 cm in diameter) of a 35 mm tissue culture dish (Nunc) were
carried out as previously described (Perris et al., 1991b, 1993). For
the generation of Col I polymers comprising of ‘homogeneous’
concentrations of the chick PG-M/versican V0 or aggrecan, 300 m l of
a 600 m g/ml solution of rat tail Col I (Collaborative Biochemical
Products) was diluted in MEM containing 5% fibronectin-depleted
FCS (Gibco/BRL) and the proteoglycans were incorporated into the
polymerizing collagen solution at concentrations of 10-500 m g/ml. For
production of Col I polymeric substrata containing stepwise
increasing or decreasing amounts of the PG-M/versican V0 isoform,
multiple overlying layers, each containing 10, 50, 100 or 500 m g/ml
of the proteoglycan, were prepared using 150 m l of total collagen-
proteoglycan solution for polymerization of each layer. Neural tube-
neural crest explants, or isolated NC cells, were embedded into the
collagen polymer by being resuspended in 50 m l of unpolymerized
Col I solution, with and without HNK-1, 5D5 or CS56 antibodies at
an Ig concentration of 20-70 m g/ml. The solution was then aliquoted
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onto the final substratum and further polymerized for 1-2 hours at 
37°C. The depth of NC cell invasion into the polymeric Col I substrata
was established under an inverted Nikon Diaphot microscope after 16-
20 hours by estimating the plane at which the three most advanced
cells localized and using transparent calibration devices of known
thickness and the micrometric scale of the microscope focusing knob.
The data are reported in arbitrary units derived from these
measurements. Complementary video time-lapse recordings and
velocity measurements of NC cell movement through the three-
dimensional substrata were performed as previously described (Perris
et al., 1993).
RESULTS
Expression of PG-M/versican V0-V3 mRNAs
Using sequence alignments of the chick, mouse and human
PG-M/versican genes to pinpoint the splicing sites, four
primers, denoted PGM-A, PGM-B, PGM-C and PGM-D, were
designed that would discriminate between PG-M/versicans
V0-V3 transcripts. RT-PCR was initially used to study the
expression of these transcripts at various developmental stages.
Equivalently strong amplified products were obtained for V0
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Fig. 1. Qualitative and quantitative analysis of the expression levels of PG-M/versican V0-V3 transcripts during various phases of NC
development, i. e. developmental stages 15-25. (Left panels) Temporal expression of PG-M/versicans during the course of NC development
detected by RT-PCR; (right panels) corresponding quantitative mapping as determined by RPA. Numbers above the arrows indicate the size of
the amplified versus protected fragments. The comparative expression levels of the V0-V2 transcripts could be assessed in the same
autoradiogram, whereas the temporal expression levels of the V3 mRNA were determined by comparing the signals obtained for the protected
V3 fragment with the signals obtained cumulatively for the V0-V2 mRNAs. 
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and V1 at all developmental stages examined, indicating that
these mRNAs were transcribed at high levels early in
development (Fig. 1). Further quantification of the temporal
mRNA expression by RPA showed that V0 was the
predominant PG-M/versican transcript expressed during the
course of NC development, whereas V2 and V3 mRNAs were
barely detectable and estimated to be >100-fold less abundant
that the parent V0 mRNA.
Overexposure of the RPA autoradiograms revealed that the
initially poor V2 and V3 mRNA transcription markedly
increased by stages 24-25. Due to the relatively larger size of
the protected V3 fragment yielding a greater intrinsic
radioactivity, a weak and fluctuating V3 signal could be
detected throughout NC cell migration (Fig. 1). Assuming
equivalent hybridization efficiency for the V2 and V3
riboprobes, the temporal expression levels of the V3 transcript,
assessed by densitometric analysis of the autoradiograms after
proper correction for the size difference of the protected
fragments, appeared somewhat lower than of the V2 (Fig. 1).
In contrast, the temporal expression patterns of the V0 and V1
mRNAs were closely similar, being elevated at stages prior to
the onset of NC cell migration and showing a rapid decline
during the course of cell movement and the formation of the
peripheral nervous ganglia. When NC cell movement and
maturation of the peripheral nervous structures was complete,
V0 and V1 mRNA transcription was upregulated and this
increased mRNA expression coincided with the initial
transcription of the V2 mRNA (Fig. 1).
Whole-mount and tissue section in situ hybridizations with
four different cDNA probes (Fig. 2A) indicated that, just prior
to the onset of NC cell migration (stage 15), the weak V0/V1
transcription occurred primarily in the ectoderm, neural tube
and notochord, whereas little or no expression of these mRNAs
could be detected within the somites (not shown). In contrast,
a clearly positive signal could be observed in the ectoderm,
neural tube, notochord, ventral portion of the sclerotome,
dorsal dermomyotome and the periaortic regions, at stages of
advanced NC cell movement, (stages 17-18; Fig. 2B,C). PG-
M/versican expression was particularly pronounced in the
floor plate, the mesonephric ducts, wing and limb bud
mesenchymes, and the lateral plate non-segmented mesoderm.
Whole-mount hybridization revealed a rather uniform
sclerotomal distribution at trunk axial levels corresponding to
regions of active NC cell movement, whereas more anterior
axial levels had a PG-M/versican expression displaced to the
caudal portion of the sclerotome. PG-M/versicans were also
widely expressed in cranial regions containing actively
moving/differentiating NC cells (Fig. 2D).
During the final phases of trunk NC cell dispersion, PG-
M/versican mRNA transcription became markedly polarized
within the sclerotome, being concentrated in its more ventral
regions, and within the notochord, where it accumulated in its
dorsal half (Fig. 2D,E). In the neural tube, PG-M/versican
transcription became gradually displaced to its luminal side
(Fig. 2E). At stages of gangliogenesis, PG-M/versican
expression along the body axis was fully metameric (Fig. 2F),
as seen in whole-mount hybridizations of aggrecan and link
protein (Kenny and R. P., unpublished data), and was also seen
in the aggregated sensory ganglia (Fig. 2G), and was
presumably associated with Schwann cells and other
supporting glial cells. A further polarization of PG-M/versican
expression was noted at these stages within the neural tube,
becoming confined to the luminal portion and excluded from
the marginal zone. PG-M/versican expression strongly
diminished in the floor plate, notochord (being solely present
in a dorsal rim), and medial ventral sclerotome at axial levels
of the ganglia, whereas it was still pronounced at intermediary
Fig. 2. (A-G). Whole-mount (B,D,F) and tissue section (C,E,G) in
situ hybridizations with the indicated PG-M/versican cDNAs probes.
(A) V0 domain structure, according to Shinomura et al., (1993), and
the relative position of the cDNA probes used in this study (sense
orientation indicated by the suffix ‘a’ and antisense by ‘b’). CSa and
CSb denote the glycosaminoglycan-attachment domains, which are
deleted in the V1 and V2 isoforms, respectively, whereas V3 lacks
both these domains (compare with Fig. 1). M6b corresponding to the
highly conserved 5 ¢ globular domain was found to cross-hybridize
with the aggrecan gene. The other probes were found to yield equal
hybridization efficiency and were used interchangeably. Dashed lines
in orange indicate the approximate trunk level represented by the
tissue sections in C, E and G. Green arrows, the metameric
distribution of PG-M/versican mRNA gradually established in a
rostral-to-caudal sequence; yellow arrowheads, strongly positive
ectodermal-mesenchymal ridges at level of the wing and limb buds;
light blue arrows, a sensory ganglion exhibiting PG-M/versican
expression. Note the progressive exclusion of PG-M/versican
expression in the presumptive chondrogenic areas, i. e.
perinotochordal area and lateral neural tube (Fig. 5). Developmental
stages, (B,C) stage 17; (D,E) stage 19; (F,G) stage 23. 
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axial levels (Figs 2G and 3D-F). PG-M/versican expression
remained absent from the developing myotomes, but was
intensified in the periaortic region, developing dermis and the
mesenchyme lining the developing gut. Strong expression was
observed in the ectodermal layer of the limb and wing buds, as
well as throughout the prechondrogenic mesenchyme of
these structures (Fig. 2G; Kimata et al., 1986; Yamagata et al.,
1993).
Tissue distribution of PG-M/versicans, aggrecan and
their putative glycosaminoglycan moieties
At stages preceding and concurrent with the onset of NC cell
migration, staining with anti-PG-M/versican antibodies was
prominent in the subectodermal space, around the neural tube
and the notochord and, in addition, some punctate staining
could be observed within the epithelial somites
(Fig. 3A). In contrast, the anti-chick aggrecan
antiserum was only weakly reactive with the
perinotochordal membrane (not shown).
Immunolabellings with anti-PG-M/versican
antibodies largely coincided with that previously
seen with antibodies to high-to-oversulfated
chondroitin-6-sulfate, whereas the staining pattern
observed with the anti-aggrecan antiserum A1
largely corresponded to that previously reported
with a number of anti-keratan sulfate, anti-
chondroitin-4-sulfate and anti-unsulfated
chondroitin antibodies (Perris et al., 1991a; Perris,
1997), as well as that observed here with the novel
anti-native chondroitin-4-sulfate mAb 4C5 and
mAb 4G2 (Table 1). These patterns were
maintained throughout the course of NC cell
migration (stages 17-20; Fig. 3B,C). Double
labelling with the CS56 and HNK-1 antibody
clearly showed that NC cells invading the rostral
sclerotome did so by entering a PG-M/versican-
rich ECM, which was progressively displaced to
the caudal portion of the sclerotome (Fig. 4A).
Similar HNK-1/antiserum A1 double labellings
also demonstrated that NC cells migrating
ventrolaterally toward presumptive neuronal sites
progressed at a considerable distance from the
aggrecan-rich perinotochordal ECM (Fig. 4D,E).
Conversely, the aggrecan-free but PG-M/versican-
rich subectodermal space was not found to
constitute a transiently impenetrable ‘barrier’ for
dispersing NC cells since some early migrating
cells were fully capable of invading this region
(Fig. 3F).
To ascertain whether the previously reported
distribution of chondroitin sulfate-bearing
proteoglycans in the caudal portion of the somites
(Tan et al., 1987; Landolt et al., 1995; Henderson
et al., 1997) could be attributed to a predefined
organization of PG-M/versicans or whether it was
dependent upon the regional movement of the cells
(Perris, 1997), a portion of the premigratory NC
was ablated and the sclerotomal PG-M/versican
distribution was examined in somites largely
lacking migrating NC cells. Single and combined
stainings with the HNK-1 antibody and the anti-
PG-M/versican antiserum showed that distribution of these
proteoglycans remained uniform within the somites deprived
of invading NC cells. In contrast, PG-M/versicans were
excluded from the somitic regions occupied by migrating cells
in the adjacent unoperated axial levels (Fig. 4A-C).
Following formation of the peripheral nervous ganglia, PG-
M/versicans were widespread throughout the sclerotome,
within the subectodermal space, and in the perinotochordal and
periaortic regions (Fig. 3D-F). Immunostainings with mAb
MY174 revealed a particularly intense deposition of PG-
M/versicans in the perinotochordal/periaortic areas and a
definite exclusion of these proteoglycans from the NC-derived
sensory ganglia, the ventral axonal bundles and the developing
myotomes (Fig. 3F). Similar staining patterns were observed
with mAbs 5C12 and 2C12, whereas mAbs 4C5 and 4G2
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Fig. 3. Representative immunohistochemical stainings observed with the anti-PG-
M/versican antibodies indicated on each micrograph. Developmental stages and
axial levels were as follows: (A) stage 16 midtrunk; (B) stage 17 midtrunk;
(C) stage 18 limb bud region; (D) stage 23 wing bud region; (E) stage 22
midtrunk; and (F) stage 23 wing bud region. Both the ventral motor axons covered
by the presumptive NC-derived Schwann cells (arrows) and the dorsal sensory
ganglia (arrowhead) were consistently devoid of PG-M/versicans. Note also the
denser distribution PG-M/versicans in the ventral regions of the embryo, when
compared to the more dorsal ones, both during the course of NC cell movement
and following the formation of the peripheral nervous ganglia. Abbreviations: nt,
neural tube; n, notochord; s, somite; dm, dermomyotome; sc, sclerotome; m,
myotome; ao, aorta. Magnifications: A, · 230; B, · 350; C, · 120; D, · 410;
E, · 130; F, · 440. 
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showed a more restricted distribution (not shown). Aggrecan
was confined to the prechondrogenic region, where it
demarcated a nonpermissive area for the extending ventral
motor axonal bundles ensheathed by NC-derived Schwann cell
precursors (Fig. 3D). During the course of NC cell movement
and peripheral gangliogenesis/chondrogenesis, we (on the
protein level) and others (on the mRNA level; Bundy et al.,
1998) have noticed that the aggrecan distribution in the
prechondrogenic mesenchyme becomes progressively
metameric emanating dorsolaterally and ventrally from the
perinotochordal regions at axial levels intermediary to those
occupied by the ganglia. Eventually, the aggrecan-containing
ECM entirely encapsulates the neural tube at axial levels
between the ganglia and delineating the prechondrogenic tissue
in the process of forming the presumptive vertebrate column
(Fig. 5). Interestingly, in contrast to the perinotochordal
aggrecan, the core protein of this ‘perineural aggrecan’ does
not seem to carry either keratan sulfates or the HNK-1 antigen
and is therefore reminiscent of that proposed to be expressed
around the early notochord (Domowicz et al., 1995).
Furthermore, the staining pattern obtained here with mAbs
4C5 and 4G2, and the previously observed stainings with mAb
4D3 (Perris et al., 1991a), indicate that PG-M/versicans
deposited in the perinotochordal region and along the
ventrolateral neural tube surface may preferentially bear
dermatan sulfate/chondroitin-4-sulfate chains.
Fig. 4. Immunohistochemical distribution of PG-
M/versican core proteins in relation to their
chondroitin sulfate moieties, aggrecan core protein
and migrating NC cells detected by the HNK-1
antibody. Antibodies used in the single and double-
labelling experiments are indicated. (A) Longitudinal
section through the midtrunk portion of a stage 17
embryo showing the distribution of migrating NC
cells in relation to the total bulk of immunolocalized
PG-M/versicans. Cells migrate through the rostral (r)
portion of the sclerotome (light red), while the
proteoglycans progressively reorganize to the caudal
(c) portion (light green), following an anterior-to-
posterior (a « p) sequence, which accompanies cell
compaction of the cells to form the dorsal sensory
ganglia. (B,C) The same sagittal section through the
midtrunk portion of a stage 18 embryo, in which a
segment of the premigratory NC was surgically
removed. PG-M/versicans become progressively
excluded from the area occupied by the advancing NC
cells. (D,E) Transverse sections through the midtrunk
regions of embryos at stages 23 (D) and 18 (E)
showing the perinotochordal extension of aggrecans
(red) (comprising both molecules substituted with
oligosaccharides embodying the HNK-1 epitope and
molecules lacking such moieties) in relation to: the
extending ventral motor axons (empty arrowheads),
including the prospective NC-derived Schwann cells and individual NC cells (filled arrowhead) migrating in the subaortic region (all green).
(F) Single NC cells (light red) migrating along the dorsolateral subectodermal pathway, which is entirely enmeshed in an ECM rich in PG-
M/versicans (green). 
Fig. 5. Immunolocalization of aggrecan core protein at stages
following gangliogenesis and concurrent with chondrogenesis,
viewed in sequential sections through the midtrunk region of a stage
24 chick embryo. Note the condensation of the perinotochordal cells
in process of differentiating into chondrocytes and the aggrecan-
positive subchordal structure eventually giving rise to the dorsal
spines of the vertebral column. At these stages, the dorsal peri-neural
tube extension of aggrecan is still alternating in a metameric fashion
the distribution of the sensory ganglia: (A,B) correspond to a





Analytical gel permeation chromatography showed that large Mr
chondroitin sulfate-bearing proteoglycans recognized by anti-
PG-M/versican antibodies had a Kav of 0.26 (Fig. 6A). These
proteoglycans were not reactive with the anti-aggrecan antiserum
A1 (not shown) and were predominantly substituted with
chondroitin-6-sulfates, as judged by the coincident reactivity with
anti-chondroitin sulfate mAb CS56 (Fig. 6A) and the
chondroitin-6-sulfate-specific mAb 3B3 (Perris et al., 1991a), and
the poor-to-absent immunoreactivity with mAbs 1B5 (unsulfated
chondroitin), 2B6 (chondroitin-4-sulfate/dermatan sulfate), 10E4
(anti-heparan sulfate), 5D4, 4D1, 2B3 and 3B2 (keratan sulfate;
not shown). Both silver/Alcian blue staining and immunoblotting
of the proteoglycans resolved by SDS-agarose gel electrophoresis
indicated a high degree of polydispersity, which greatly surpassed
that observed for PG-M/versicans from adult mammalian tissues
(Schmalfeldt et al., 1998; M. Schiappacassi, D. P., S. Cattaruzza,
P. Spessotto, A. C. and R. P., unpublished data).
Some material reactive with mAb MY174 eluted with
apparent lower hydrodynamic sizes (especially when deriving
from more advanced stages of development; Fig. 6A). The
nature of this MY174-reactive proteoglycan was not examined,
but it may correspond to naturally occurring degradation
products of PG-M/versicans similar to those found in the adult
human brain (Perides et al., 1996). The possibility also remains
that the MY174-immunoreactive material may represent
additional uncharacterized splice variants of the PG-
M/versican, which, similarly to the V3 isoform, may lack
glycosaminoglycan chains.
Several rounds of ion-exchange chromatography were
needed to separate PG-M/versicans. In the first one, they
were retrieved in a sequential manner after NaCl elution,
starting at 0.41 M and ending at 1.2 M (Fig. 6B). A second
ion-exchange chromatography by HPLC on Mono-Q
columns, eluted with a linear LiOCl4 gradient, yielded a
comparable but sharper chromatographic profile. The first
peak eluting at 0.22 M showed the highest protein content
(Fig. 6B), as confirmed by comparative adsorbance readings
at 214, 260 and 280 nm (not shown). PG-M/versican-
containing fractions were analyzed by immunoblotting with
and without prior enzymatic digestion with heparitinase III
(not shown), chondroitinase ABC and endo- b -galactosidase
(Fig. 6B). Endo- b -galactosidase digestion did not alter the
electrophoretic mobility of the proteoglycans and similar
results were obtained after digestion with either keratanase I
or keratanase II (not shown). Comparisons of the relative
electrophoretic mobilities of an unreduced IgM ( ~ 900 kDa)
molecule, intact EHS laminin-1 (approx. 1,000 kDa) and
intact tetramers of collagen type VI (~ 2,400 kDa), showed
that the molecular sizes of the isolated PG-M/versicans fell
within an apparent Mr range of 1,200-2,000,000.
Upon chondroitinase ABC digestion, a series of >7
discernible bands, with the slowest migrating and most intense
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Fig. 6. Analytical and preparative chromatographic
separation of PG-M/versicans expressed the during the
course of NC cell migration and gangliogenesis.
(A) Analytical separation of PG-M/versicans expressed
in the trunk region at initial phases of NC cell migration
(stage 15; St 15), advanced migration (stage 17; St 17)
and following gangliogenesis (stage 23; St 23), and their
identification by immunoassays using mAbs MY174,
5D5 and CS56. Graphs show the elution profiles of gel
permeation chromatographs on CL-2B Sepharose
obtained by ELISA on the eluted fractions with the
indicated antibodies. S/Ab refer to silver/Alcian blue-
stained proteoglycans, which were pooled and ethanol
precipitated from fractions 17-34, and resolved by SDS-
agarose gel electrophoresis. At any given stage, the
major bulk of PG-M/versicans eluted immediately after
the void volume of the column (V0), whereas some
chondroitin sulfate-free material reactive with both
mAbs 5D5 and MY174 eluted with the total volume of
the column (Vtot). (B) Purification of PG-M/versicans
expressed along the NC migratory routes at advanced
stages of movement (stage 17) by ion-exchange
chromatographs on DEAE Sepharose (left panel) and
Mono-Q columns (right panel) eluted with linear
gradients of NaCl or LiClO4. Elution from DEAE
Sepharose columns was monitored by ELISA and
immunoblotting using mAb 5D5, whereas Mono-Q
chromatographs were monitored by adsorbance readings
at 214 and 280 nm. In both chromatographic separations, two major peaks were detected, which are indicated by dark-red and dark-blue arrows,
respectively. Due to the minute amounts of proteoglycan contained by the second peak (dark-blue arrow), the content of this latter peak was not
further investigated. The material contained by the peak indicated by the dark-red arrow was further analyzed by immunoblotting with and
without prior chondroitinase ABC (Chase) and endo- b -galactosidase (Endo b gal) digestion and using the indicated antibodies. Position of the
molecular weight standards, including the a 1 chain of EHS laminin-1 (400 kDa), an IgM-class immunoglobulin (950 kDa), thyroglobulin (669
kDa), ferritin (440 kDa), catalase (232 kDa), myosin II (205 kDa), b -galactosidase (116 kDa) and phosphorylase (97 kDa) is indicated for the
different immunoblots. 
A
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bands recognized by mAbs 5D5 and MY174 and the anti-PG-
M antiserum resolving at 490-510 kDa and at 490-530 kDa,
and the fastest migrating one recognized primarily by mAb
5D5 resolving at 215-225 kDa (Fig. 6B). Intermediate
immunoreactive bands ran at 390, 350, 280 and 245 kDa. The
material obtained after elution of Mono-Q columns with LiOCl4
exhibited partly overlapping traits with two major, heavily
glycosylated PG-M/versican core protein populations migrating
at 490 and 360 kDa, followed by two bands at 280 and 215-220
kDa, which were intensely stained by mAb 5D5, but only
weakly labelled by the anti-PG-M antiserum and mAb MY174
(Fig. 6B). These lower Mr bands are presumed to correspond to
degradation products. Moreover, in this material, the 390 and
245 kDa bands were less abundant than after ion-exchange
chromatography combined with NaCl elution. Conclusively, the
immunoblotting banding pattern observed for early embryonic
PG-M/versicans purified according to the herein adopted
purification procedures was concordant with that previously
reported after immunoblotting of whole tissue extracts with
mAb MY174 and of late embryonic PG-M/versicans V0 and
V1 of various tissue origins (Yamagata et al., 1993).
Ultrastructural traits of PG-M/versicans
When examined by TEM involving rotary shadowing, PG-
M/versicans purified from the trunk region of embryos at stages
of advanced NC cell migration exhibited the characteristic
bi-globular appearance and seemed to carry relatively few
extended side chains (Fig. 7A,C). The ultrastructural
appearance of these molecules was compared to that of the
previously described for bovine aorta PG-M/versican V1/V2
isoforms (Mörgelin et al., 1989). Comparative length
measurements of the stretched proteoglycan molecules showed
a relative size distribution of the isolated core proteins that was
consistent with the expected lengths for V0 and V1 isoforms
(Fig. 7B,D). Moreover, the size distribution observed in
proteoglycans isolated from the NC migratory pathways
B
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indicates a more homogeneous population of molecules and
was compatible with the mRNA expression data showing a
prevalence of the PG-M/versican V0 isoform. Accordingly, a
significantly greater number of embryonic trunk proteoglycan
molecules had an approximate length of 400 nm (Fig. 7B,E),
whereas the less represented putative V1 isoform was 50-100
nm shorter (Fig. 7B,F). Differences in apparent molecular
homogeneity in the avian embryonic and bovine adult
preparations could indicate that embryonic trunk PG-
M/versicans are more homogeneously glycanated, such as to
render the core proteins more uniformly stretchable during
sample preparation. Interestingly, although the putative
embryonic V1 isoform only differs from the V0 isoform in the
lack of a relatively short glycosaminoglycan-binding domain, it
seemed to carry significantly fewer and more elongated chains
than those present on the V0 isoform (Fig. 7E,F).
‘Redirection’ of NC cell migration in vivo by
orthotopical implantation of PG-M/versicans bound
to micromembranes
To compare the effects of PG-M/versicans and aggrecans on
NC cell migration in vivo, purified proteoglycans were
immobilized onto micromembranes and implanted into the
migratory pathways of the NC prior to the onset of migration.
This type of implantation created two distinct experimental
situations: (1) the orthotopic implantation of purified PG-
M/versican isoform V0, a mixture of V0/V1, or a mixture of
V1/V2, resulted in dispersing cells being confronted with a
locally enhanced concentration of either of these PG-
M/versican isoforms/isoform combinations, and (2) ectopic
implantations of a notochordal-like aggrecan caused migrating
cells to be confronted with the heterotopically localized
proteoglycan.
When either proteoglycan- or fibronectin-coated
micromembranes (the latter ones used as reference due to the
well-established motility-promoting activity of fibronectin in
vitro and in vivo) were implanted into regions lacking active
NC cell migration, they did not exert any overt effect on
the pattern of NC cell migration (not shown). In fact,
micromembranes inserted into either the most ventrolateral
region of the sclerotome (at level with the pronephric ducts),
or adjacent to the notochord, neither attracted cells into those
areas nor caused any other abnormalities in the migration of
the cells. This indicated that implantation of micromembranes
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Fig. 7. Ultrastructural analysis of
PG-M/versicans extracted from
embryonic trunks of stage 17 chick
embryos (A,E,F) and from adult
bovine aorta (C). Arrows point to
the predominant molecular species,
based on core protein length
measurements. Arrowhead in A
points to a putative PG-M/versican
V1 isoform shown at high power in
F. Arrowheads in E point to the
globular domain of a PG-
M/versican V0 isoform. (F) Close
up of the putative V1 isoform
showing the relatively few and
extended glycosaminoglycan chains
(arrow) attached to this isoform.
(B,D) Graphic representations of the
relative frequencies of the
differently sized PG-M/versicans in
each preparation (based upon the
lengths measured for their core
proteins). 
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per se did not elicit secondary effects on cell movement.
Similarly, uncoated micromembranes and fibronectin-coated
micromembranes that were implanted into areas invaded by
the dispersing NC cells did not significantly affect their
migratory behaviour and, hence, cells advanced over both
sides of the membranes (Fig. 8A,B; Table 2). However, in
about 30% of the fibronectin implants, cells tended to deviate
from their normal trajectory and move toward the implants
(Table 2).
Micromembranes coated with the avian fibroblast PG-
M/versican V0, the embryonic trunk V0/V1 or the bovine
aorta V1/V2 isoforms had variable effects depending upon:
the isoform combination, the location of the implant, and the
developmental stage at which the effect of the implant was
evaluated. Thus, if the proteoglycan implants localized
within the NC migratory pathways (Fig. 8A), there was a
‘directed’ migration towards the implants in >50% of the
cases. The degree of deviation seemed to be determined by
whether the implant was localized within the dermomyotome
or in the dorsal sclerotome (Table 2), whereas, if positioned
within the subectodermal space, there were simply more
cells entering this space than in the contralateral side. In
contrast, if the PG-M/versican-coated micromembranes
localized within the medioventral sclerotome/mid-
dermomyotome, the apparently ‘redirected’ NC cell
migration towards the implanted membrane was observed in
>70% of the cases (Fig. 8D,E; Table 2). The deviation from
the normal migratory trajectory in response to the
proteoglycan implants was most pronounced for ventral
motor axons and NC-derived Schwann cell progenitors (Fig.
8F). In contrast, when implants were localized in the
endogeneously PG-M/versican-rich ventral portion of the
sclerotome, migrating NC cells encountering them tended to
circumvent the implants, even when these were oriented
perpendicularly to the migratory trajectory of the cells (Fig.
9A,B). Thus, in these cases, it seemed that the local
environment was more ‘attractive’ than that provide by the
PG-M/versican implant.
Perturbation of NC cell migration in vivo by
heterotopical implantation of micromembrane-
bound aggrecans
In contrast to the apparent ‘attracting’ effect of PG-
M/versicans, cell movement was consistently perturbed when
aggrecan-coated micromembranes were implanted into the NC
migratory pathways or within the medioventral sclerotome
(Fig. 8A,D,G). Two types of alterations were then observed:
(1) NC cells either associated with the surface of the
micromembrane, often in smaller clusters, and exhibited an
impaired ventral progression when compared to the
controlateral reference side of the embryo, or (2) NC cells
deviated spatiotemporally from their normal migratory
trajectory by spreading over one or both surfaces of the
implanted micromembrane. The most marked effect was
observed when aggrecan-coated micromembranes were
inserted into the dorsal portion of the sclerotome (Fig. 8C,H,I;
Table 2), suggesting that early migrating cells were particularly
susceptible to direct confrontation with the heterotopic
implant. In this position, the micromembranes caused an
apparent arrest of NC cell movement in ~ 80% of the cases
(Table 2).
NC cell movement was also blocked when aggrecan-coated
micromembranes were introduced into the ventral portion of
the sclerotome, resulting in NC cells being trapped close to
the implant. Ultrastructural analysis of the cell-
micromembrane interface showed that NC cells localizing in
juxtaposition with the aggrecan-coated micromembrane
established contacts with it focally through plasma membrane
protrusions (Fig. 9E,F). However, the cells did not form
typical electron-dense contacts, such as those previously
observed in filopodia of migrating NC cells interacting with
interstitial collagen fibrils (Perris et al., 1990). NC cells
Table 2. Effects of topical implantation of proteoglycans on NC cell migration
Percentage of embryos showing affected NC cell migration 
Total % of according to the final localization of implant (n=total)4
Total embryos showing 
number of affected NC cell Dorsal Subectodermal Dermomyotome Ventral 
Implanted molecule1 embryos2 migration3 sclerotome (A) space (J) (G) sclerotome (D)
None 14 14 0 (7) 0 (1) 0 (3) 0 (3)
PG-M-V0 19 79 42 (8) 100 (2) 100 (3) 11 (6)
PG-M-V0/V1 3 67 100 (1) – – 50 (2)
PG-M-V1/V2 9 67 80 (5) – 50 (2) 50 (2)
CNLA 28 78 91 (11) 100 (3) 66 (6) 89 (9)
CNLA-Chase 17 47 54 (13) 0 (0) 50 (2) 50 (2)
CNLA-Chase+Eb g 16 17 18 (11) 0 (0) 0 (2) 34 (3)
HA-aggrecan 11 45 67 (6) 0 (0) 0 (1) 34 (3)
Fibronectin 17 29 12 (8) 0 (2) 0 (3) 18 (4)
1Purified ECM molecules immobilized onto micromembranes and implanted into various regions of the living embryo were: PG-M/V0, PG-M/versican
isoform V0 from cultured chick fibroblasts; PG-M-V0/V1, PG-M/versican isoforms isolated from NC migratory pathways; PG-M-V1/V2, PG-M/versican
isoforms V1/V2 from bovine aorta; CNLA, chick notochordal-like aggrecan; CNLA-Chase, chondroitinase ABC-digested aggrecan; CNLA-Chase+E b g,
chondroitinase ABC and endo- b -galactosidase-digested aggrecan; HA-aggrecan, native multimeric hyaluronan-aggrecan complexes from bovine nasal cartilage
2Each embryo received a unilateral implant
3Refers to both impaired progression of NC cells along the normal migratory pathways upon contact with the proteoglycan implant and “redirected” NC cell
movement towards the implant
4Embryos showing affected NC cell migration had either cells in close apposition (and mostly clustered) to the implanted micromembranes (aggrecan) or
redirected migration towards the implant (PG-M/versicans). Codes within brackets refer to the corresponding schematic panels of Fig. 8, where final positions of
the implants are defined as follows: (A) dorsal sclerotome; (J) apical subectodermal space; (G) medial sclerotome/mid-dermomyotome; and (D) ventral
sclerotome.
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juxtaposed to aggrecan-coated micromembranes tended to
cluster in about 60% of the cases examined. In contrast,
control uncoated micromembranes and micromembranes
coated with fibronectin, seldom had closely apposed cells
(11% and 23% of the cases, respectively, n=14-17) and did not
cause cluster formation in association with the membrane
surface (0% and 6% of the cases, respectively).
Aggrecans and PG-M/versicans are assembled in the ECM
in the form of oligomeric complexes arranged along a central
hyaluronan filament and such native assemblies can be isolated
D. Perissinotto and others
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from bovine nasal cartilage and cultured rat chondrosarcoma
cells (Mörgelin et al., 1989, 1992). We therefore implanted
multimeric hyaluronan-aggrecan complexes bound onto
micromembranes to determine whether the inhibitory effects
of aggrecan would be exerted also in its naturally occurring
macromolecular configuration. Intriguingly, these implants
were substantially less effective in perturbing cell movement
when compared to the monomeric aggrecan (Table 2). This
discrepancy was not simply due to an intrinsic species-related
difference in the monomeric bovine and rat aggrecan versus
chick aggrecan, since, in their monomeric forms, these
aggrecans caused similar effects to those seen with the chick
aggrecan (data not shown). Aggrecan-coated micromembranes
implanted into the subectodermal space (Fig. 8J) caused a
similar effect to PG-M/versican implants into this region: NC
cells remained associated with the membrane in a somewhat
more advanced position in comparison to that of the
contralateral side (Fig. 8K). However, NC cells retained on the
surface of the subectodermally positioned proteoglycan-coated
micromembrane were less advanced when compared to cells
migrating along the same route at more anterior axial levels
(Fig. 8L). This observation further confirms the generalized
nonpermissive effect of aggrecan on NC cell migration.
Furthermore, it is unlikely that the disparate effects seen for
aggrecan and PG-M/versicans could be of a quantitative nature.
This since lowering of the amount of proteoglycan coated onto
membranes still caused the same type of effect, but with lower
efficacy, similar results were also observed when using
aggrecans from other tissue and species sources (data not
shown).
The potential involvement of the chondroitin and keratan
sulfate chains of the aggrecan in mediating its nonpermissive
effects of NC cell migration has previously been proposed in
vitro (Perris et al., 1996) and was explored here also in vivo
by coating micromembranes with the chondroitinase ABC, or
combined chondroitinase ABC/endo- b -galactosidase, digested
aggrecan. Both of these enzymatic treatments strongly reduced
the ability of aggrecan to perturb NC cell migration with the
strongest effect seen after removal of both types of
glycosaminoglycan chains (Fig. 9C,D; Table 2). In these cases,
dispersing cells that encountered the implanted modified
proteoglycan failed to establish close contacts with it (Fig. 9D).
Effects of PG-M/versican V0 and aggrecan on NC
cell migration through three-dimensional Col I
substrata
NC cells migrate poorly through three-dimensional collagen
substrata, but their movement can be enhanced by
copolymerization of fibronectin (Perris et al., 1991b). This
finding, as well as the inhibitory effect of the bovine nasal
cartilage-derived aggrecan observed in previous experiments,
were confirmed here using the chick notochordal-like aggrecan
(Fig. 10). In contrast, copolymerization of the PG-M/versican
V0 isoform created a Col I three-dimensional substratum that
allowed for a significant movement of NC cells away from the
neural tube explant and invasion of the polymer (Fig. 10).
Movement of NC cells through the Col I-PG-M/versican V0
substratum was strictly dependent upon the concentration of
the copolymerized proteoglycan, whereas the inverse
relationship was observed at increasing concentrations of
aggrecan (Fig. 10). NC cells were also confronted with
polymeric Col I substrata in which the PG-M/versican V0
isoform was incorporated into the polymer at stepwise
increasing or decreasing concentrations. In these cases, NC cell
movement through Col I-PG-M/versican polymer was
comparable to that observed with homogeneous concentrations
of the proteoglycan and in Col I-fibronectin polymers (Fig. 10).
In contrast, movement was markedly impeded when NC cells
were confronted with a ‘reverse gradient’, i.e. the highest
concentration first and progressively lower concentrations of
the proteoglycan.
Addition of antibody HNK-1 did not significantly block the
poor migration in the Col I polymer alone, or in the
copolymerized Col I-fibronectin gel, but significantly inhibited
NC cell movement through the Col I-PG-M/versican V0
substratum (Fig. 10). Antibodies MY174 and 5D5 binding
close to the G1 globular domain (Table 1; M. Schiappacassi,
D. P., S. Cattaruzza, P. Spessotto, A. C. and R. P., unpublished
data) did not alter the migratory behaviour of the cells (data
not shown). These preliminary observations are consistent with
a NC-PG-M/versican interaction mediated by the C-terminal
G3 globular domain (Perris et al., 1996). Video time-lapse
recordings of these cell movements indicated a somewhat
lower velocity for NC cell migrating through Col I-PG-
M/versican V0 when compared to Col I-fibronectin (43
m m/hour, n=16 versus 67 m m/hour, n=22), but an apparent
higher degree of directional movement in the latter three-
dimensional substratum, which was not further quantified.
Furthermore, as previously suggested (Perris, 1997), NC cell
Fig. 8. Effects of fibronectin- and proteoglycan-coated
micromembrane implants on NC cell migration in vivo when
evaluated by immunofluorescence and confocal laser microscopy of
serial transverse sections from roughly comparable axial levels of
stages 17-20 embryos. Migrating NC cells were evidenced by
indirect immunohistochemical labellings with the HNK-1 antibody
followed by detection with fluorescein- or Texas Red-conjugated
secondary antibodies. Final positions of the micromembranes are
indicated schematically for the most representative cases in the left
panels (A,D,G,J). These also indicate the two major NC migratory
routes in the chick embryo (arbitrarily denoted primary and
secondary migratory pathway, respectively). Molecules coated onto
the micromembranes are indicated: FN, fibronectin; CCA, chick
notochordal-like aggrecan; PGM V0, avian PG-M/versican V0;
PGM V1, bovine aorta PG-M/versican V1/V2; BHA, link protein-
stabilized hyaluronan-aggrecan complex from bovine nasal
cartilage. Position of the micromembrane implants are indicated by
the white arrows, except for inset in B in which the position of the
implant is indicated by the red arrow. (K) The micromembrane (M)
has been pseudocolored in violet. (F) Note how the extending
ventral motor axons, which are encapsulated by the presumptive
NC-derived Schwann cells, have been redirected towards the PG-
M/versican implant. Link protein-stabilized hyaluronan-aggrecan
complexes also retained migrating NC cells in the vicinity of the
membrane surface (I). Dorsolaterally migrating NC cells that
encountered PG-M/versican and aggrecan-coated micromembrane
progressed over the surface of the membrane as for analogous
implants in other locations of the embryo. Developmental stages
and axial levels are as follows: B, stage 17 lower trunk; C, stage 18
wing bud; E, stage 17 lower trunk; F, stage 20 midtrunk; stage 17
wing bud; I, stage 19 limb bud; K, stage 17 lower trunk; L, stage 17
midtrunk. In the pseudocolored confocal laser microscopy
photographs in K and L, red indicates the most intense
fluorescence. 
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movement through these three-dimensional collagen substrata
was dependent upon the activity of b 1 integrins (not shown).
DISCUSSION
The experiments in this study suggest that PG-M/versicans
may not act as ‘barrier molecules’ exerting a repellent effect,
but may rather function as pivotal cell-interactive elements of
the interstitial ECM lining the NC migratory routes. In fact,
PG-M/versicans were found to be widely expressed at both
mRNA and protein level in tissues consituting the NC
migratory pathways and to favor NC cell movement in vitro
and in vivo.
The spatiotemporal distribution of PG-M/versicans did not
inversely correlate with the migratory tracks of NC cells.
Conversely, laterally and medially migrating NC cells were
found to be surrounded by a dense PG-M/versican ECM at all
phases of migration and the tissue-specific reorganization of
these proteoglycans seemed to be a direct consequence of NC
morphogenesis. For instance, the transition from an initially
uniform to a preferentially caudal arrangement of sclerotomal
PG-M/versicans is correlated with the progression of NC cell
migration through the rostral portion and is firmly dependent
upon this metameric migratory pattern. Thus, our findings
support the previously reported segmental distribution of
sclerotomal PG-M/versicans at advanced-to-final phases 
of NC cell migration (Tan et al., 1987; Landolt et al., 1995;
Henderson et al., 1997), but reject the proposed occurrence
of a premigratory, patterned PG-M/versican distribution
responsible for the segmental migration of NC cells along the
body axis. On the contrary, distribution of aggrecan was found
to be strictly confined to the migration-nonpermissive area
around the notochord, to exhibit segmental variations in its
dorsolateral extension as recently suggested by mRNA studies
D. Perissinotto and others
Fig. 9. (A-D) Migrating NC cells detected by the HNK-1
antibody in embryos that had received micromembrane
implants (arrows) of intact and enzyme-digested
proteoglycans in dorsal and ventral regions of the
sclerotome. (A) Representative response of ventrally
migrating NC cells to V1/V2 PG-M/versican isoforms
from bovine aorta. In these cases, NC cells migrated both
along the micromembrane surface as well as beyond it
largely bypassing it. (B) A ventrally positioned PG-
M/versican V0 implant which, in that location, fails to
‘attract’ the extending ventral axon bundles and associated
NC-derived Schwann cells. (C) Chondroitinase ABC-
treated aggrecan (CCA-Chase) fails to entrap the majority
of the ventrally migrating NC cells in it close proximity.
(D) Migrating NC cells encountering a chondroitinase
ABC/endo- b -galactosidase-digested aggrecan (CCA-C/E)-
carrying micromembrane entirely avoid the implant.
(E,F) TEM micrographs portraying an overview (E) and an
enlargement (F) of the boxed area in sections taken from
the ventral sclerotome of the midtrunk region of a stage 18
embryo in which an aggrecan (CCA)-coated
micromembrane (M) had been implanted. Arrowheads
point to the contact zones between the plasma membrane
of migrating NC cells (nc) and the surface of the implant.
White arrow points to the NC cell filopodium protruding
over the surface of the aggrecan-coated micromembrane. 
Fig. 10. Migration of NC cells through Col I three-dimensional
substrata into which fibronectin (FN), the chick PG-M/versican V0
isoform or the chick notochordal aggrecan had been incorporated in
different concentrations, either homogeneously distributed or in
stepwise increased/decreased amounts (i.e. PG-
M/versican10/50/100/500 and PG-M/versican500/100/50/10). NC cells were
allowed to migrate through the polymers in the presence or absence
of the HNK-1 antibody. Continuous and dashed lines correspond to
NC cell migration into polymeric Col I substrata alone, or into Col I
polymers containing 20 m g/ml FN, respectively. Data points
represent means of 7-11 cultures per experimental situation. 
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(Bundy et al., 1998), and to be remodelled by the migrating
NC cells themselves. Finally, consistent with recent
observations in the mouse embryo (Henderson et al., 1997),
neither early migrating nor preganglionic NC cells express PG-
M/versican, whereas some PG-M/versican expression could be
detected within the aggregated ganglia and was assumed to be
associated with supporting non-neuronal cells of these nervous
structures.
V0 was the ubiquitously and most abundantly expressed
PG-M/versican isoform during the course of NC cell
movement, followed by V1; whereas V2 and V3 isoforms
were substantially more weakly transcribed and/or virtually
absent at these stages of development (we did not find
evidence for the expression of other alternatively spliced
forms). In adult mouse and human tissues, the V1 isoform is
the prevailing isoform (Dours-Zimmermann et al., 1994;
Shinomura et al., 1995; Yao et al., 1996; Zako et al., 1995;
Ito et al., 1995; Schmalfeldt et al., 1998; M. Schiappacassi,
D. P., S. Cattaruzza, P. Spessotto, A. C. and R. P., unpublished
data) and this suggests that the inverse relationship in the
embryonic versus adult splicing frequency of the V0 and V1
isoforms may represent a developmentally related transition
in the RNA splicing control of this gene. Furthermore, since
it has previously been suggested that the V2 isoform may be
rather specific for the central nervous system (Schmalfeldt et
al., 1998), the weak V2 mRNA expression detected by RT-
PCR in the developing chick trunk is likely to be restricted
to the spinal cord. In situ hybridizations, which as for
immunohistochemistry allow a distinction between the V0
and V1 or V0 and V2 distribution, indicated that PG-
M/versican transcription was more elevated in the ventral
than dorsal regions of the embryo and was particularly
concentrated in ‘signalling zones’ such as the floor plate-
dorsal half of the notochord. Thus, the possibility remains
that PG-M/versicans may be involved in some of the
inductive events leading to neuronal specification within the
spinal cord.
Chromatographic separation and partial biochemical/
immunochemical characterization of PG-M/versicans
extracted from the NC migratory regions at distinct phases of
NC development, in conjunction with previous and present
immunochemistry on tissue sections, indicated that these
proteoglycans were synthesized with a higher degree of
chondroitin sulfate substitution at initial phases of NC cell
migration than later on in development. Previous and current
observations also indicated that the prevalent
glycosaminoglycan chains of these early expressed PG-
M/versicans are of the chondroitin-6-sulfate/dermatan sulfate
type, whereas, if present at all on a small number of early
embryonic PG-M/versican molecules, unsulfated chondroitin,
4-sulfated chondroitin and keratan sulfates may be primarily
restricted to the PG-M/versicans of the perinotochordal ECM.
Overall, the chick PG-M/versicans described here closely
resemble the homologous proteoglycans isolated from
amphibian ectoderm (Stigson and Kjellén, 1991; Stigson et al.,
1997a,b) and ventral trunk of quail embryos (Kerr and
Newgreen, 1997; Dillon and R. Perris, unpublished data). Our
immunohistochemical analyses further suggest that the PG-
M/versican V0/V1 isoforms deposited in the more ventral
region of the embryo may preferentially carry dermatan sulfate
chains, which similarly to keratan sulfates, are more likely to
be the ones responsible for the ‘repulsion-like’ effects exerted
on NC cell migration by the perinotochordal region.
The SDS-PAGE/immunoblotting banding pattern obtained
after chondroitinase digestion for the core proteins of the
isolated embryonic trunk PG-M/versicans was consistent with
that previously observed for whole-tissue homogenates from
late chick embryos (Yamagata et al., 1993) and isolated
mammalian and late embryonic avian V0/V1 PG-M/versican
isoforms (Habuchi et al., 1986; Kimata et al., 1986; Morita et
al., 1990; Yamagata et al., 1993; Shinomura et al., 1993; Yao
et al., 1996). Although SDS-PAGE bands at ‡ 500 kDa have
been proposed to correspond to the tissue form of PG-
M/versican V0 (Shinomura et al., 1993), data obtained here, as
well as elsewhere for bovine and human PG-M/versicans
(Mörgelin et al.,1989; Yao et al., 1996; M. Schiappacassi, D.
P., S. Cattaruzza, P. Spessotto, A. C. and R. P., unpublished
data), strongly favors the idea that the 400-500 kDa bands may
also encompass glycosylation variants of the V1 isoform.
Ultrastructural analysis by TEM involving rotary shadowing
ascertained the identity, purity and characteristic structural
traits of the embryonic trunk PG-M/versicans, showing a
prevalence of the V0 isoform and highlighting the possibility
that the V1 isoform may carry longer and significantly fewer
chondroitin sulfate chains. When compared with PG-
M/versicans isolated from adult bovine aortas, and
predominantly encompassing the V2 isoform (Mörgelin et al.,
1989; M. Schiappacassi, D. P., S. Cattaruzza, P. Spessotto, A.
C. and R. P., unpublished data), PG-M/versicans from the
early embryonic trunk seemed also more homogeneously
glycanated.
We provide functional evidence that PG-M/versicans and
aggrecan exert disparate and presumably opposed roles during
NC cell movement in vivo. Heterotopic implantations of the
purified proteoglycans into the migratory pathways of the NC
demonstrates that PG-M/versicans of the ECM encountered by
the moving cells may be conducive to migration, whereas the
presence of aggrecan, which is the major constituent of the
nonpermissive perinotochordal ECM (Pettway et al., 1990,
1996; Perris et al., 1996), inhibits NC cell movement.
Nonetheless, local implantation of PG-M/versicans into the NC
migratory pathways, or their adjacent embryonic regions, in
most cases altered the spatial pattern of NC cell movement by
‘redirecting’ moving cells toward the implant. This effect
appeared to be greater for the V1/V2 isoforms from bovine
aorta and was most obvious following orthotopic PG-
M/versican implantations into the medioventral sclerotome,
suggesting that the response of migrating NC cells to regional
accumulations of PG-M/versicans may be progressively
modulated during their ventral progression through the
embryo. On the basis of our present and previous distributional
data (Perris et al., 1991a; Perris, 1997), we propose that the
density of chondroitin sulfate-bearing proteoglycans increases
in the developing embryo in a dorsal-to-ventral orientation.
Distribution and ECM arrangement of PG-M/versicans,
as determined by in situ hybridization and
immunohistochemistry, further suggest that the previously
proposed accumulation of chondroitin sulfates in more ventral
regions of the embryo may reflect an overabundance of
proteoglycan molecules rather than an augmented glycanation
level of equivalently densely distributed core proteins.
Accordingly, NC cells progressing in the dorsal-to-ventral
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direction may move in a ‘haptotactic-like’ fashion toward
embryonic regions with denser PG-M/versican concentrations
(Perris, 1997). This idea is supported by two observations.
First, implantation of micromembrane coated with PG-
M/versicans in the dorsal sclerotome caused NC cells to move
toward the implant (more extensively than to fibronectin
implants), whereas implants in the PG-M/versican-denser
ventral portion of the sclerotome were ignored. Secondly, NC
cells migrate through polymeric Col I substrata containing
‘homogeneous’ concentrations of PG-M/versicans, but not
aggrecan, displaying a relatively high persistency in
directionality and a similar locomotory efficiency as in the
presence of fibronectin.
If NC cells were confronted with polymeric Col I substrata
containing spatially increasing concentrations of PG-
M/versicans, they migrated extensively through the polymer,
whereas a reversed concentration ‘gradient’ largely impeded the
cells’ invasion of the Col I-PG-M/versican polymer. Similar
results have been obtained when NC cells have been confronted
with increasing/decreasing concentrations of PG-M/versicans
and fibronectin in Transwell assays (R. P., unpublished data).
Finally, our in vitro data suggest that this apparently haptotactic
migratory response of NC cells to PG-M/versicans is dependent
upon the interaction of HNK-1 epitope-bearing molecules of the
NC cell surface with the C-terminal lectin C-type module of the
G3 globular domain (Perris et al., 1996). If so, this finding
would be consistent with recent observations showing that this
module of hyalectan proteoglycans binds with high-affinity to
sulfoglucuronylglycolipids characteristic of the HNK-1 epitope
(Miura et al., 1999).
In contrast to PG-M/versicans, heterotopic implantation of
aggrecan did not ‘attract’ cells toward the implant and did not
allow their free migration through the pores of the aggrecan-
coated micromembrane, when positioned to form a physical
obstacle for the ventral progression of the cells. However, when
the micromembrane-bound aggrecan was inserted into the
primary NC migratory pathway, NC cells remained in close
contact with the implant. This tethering was accompanied by
cell aggregation and may similarly have been contributed by
the previously proposed (Perris et al., 1996) lectin-binding
domain interaction with the NC cell surface HNK-1-reactive
moieties. Thus, the behaviour exhibited by NC cells
encountering ectopic aggrecan substrata in vivo was different
from that observed in vitro, presumably due the conditioning
by the natural tissue environment. The migration inhibitory
effect was more pronounced for the monomeric avian aggrecan
than for multimeric hyaluronan-aggrecan complexes from
other tissue/species. This finding opens two possibilities: (1)
the nonpermissive effect of the notochordal aggrecan is
glycanation-dependent; and/or (2) the interaction of NC cell-
associated hyaluronan with the G1 domain of aggrecan, which
is tightly engaged in the stabilization of the hyaluronan-
aggrecan-link protein complexes, is too inefficient to liberate
single aggrecan molecules for cell interaction. Accordingly, the
apparent cell-surface-associated hyaluronan-mediated arrest of
cultured NC cells in response to soluble aggrecans (Perris and
Johansson, 1987, 1990; Perris et al., 1996; Kerr and Newgreen,
1997), and the inhibited NC cell migration in response to
uncomplexed aggrecans in vivo, point to a dynamic aggrecan-
NC cell interplay that is modulated by the ECM assembly of
this proteoglycan.
Micromembrane implants carrying aggrecan deprived of its
glycosaminoglycan chains were less effective in perturbing NC
cell movement. Our previous in vitro results indicated that,
once aggrecans are allowed to freely interact with the NC cell
surface, their keratan sulfate chains may play a central role in
mediating their adverse effect on cell motility (Perris et al.,
1996; Perris, 1997). Thus, while the function of PG-
M/versicans during NC development may be dictated by their
core proteins, possibly through interactions with ECM (Tan et
al., 1987; Aspberg et al., 1997, 1999) and cell surface ligands,
the abundant and highly diversified glycan moieties of
aggrecan are likely to be the ones primarily responsible for its
inhibitory effects on cell movement. Conceivably, these
inhibitory effects may be additionally operated through a side
chain-mediated sequestration of motility-unfavorable soluble
components. Blocking the interaction of PG-M/versicans with
the cognate ECM and/or NC cell surface ligands in vitro and
in vivo, e.g. via treatment with lectin-binding molecules (Krull
et al., 1995), perturbs the pattern of NC cell migration. Thus,
collectively, these previous findings, recent studies on mutant
axolotl and mouse embryos, and our present data, suggest that
precise qualitative and quantitative ECM arrangements of PG-
M/versicans are important in guiding NC cells to their ultimate
sites. Other experiments confirm the unambiguous inhibitory
effect of aggrecans on NC cell migration, and show the cardinal
role of aggrecans in the structuring of the migration-
nonpermissive perinotochordal area. Thus, two opposed roles
are demonstrated for PG-M/versicans and aggrecans during
avian NC development.
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